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Abstract
AIM: The effects of the glucocorticoids (GR) fluticasone and budesonide and a blocker of the adenosine receptor 
in the treatment of patients with chronic obstructive pulmonary disease (COPD) and bronchial asthma were studied 
in this work.
METHODS: The parameters of lung function were determined with body plethysmography. Airway resistance (Raw) 
was registered and measured and the intrathoracic gas volume and specific resistance (SRaw) of the airways were 
also calculated.
RESULTS: The results of this study of patients with COPD and bronchial asthma used doxofylline as a blocker 
of the adenosine receptor. Doxofylline was given orally on 7 consecutive days at home with a dose of 2 × 400 mg 
orally. Raw and IGTV were then measured, and SRaw was calculated. The results indicated a significant decrease 
in the airway specific resistance (p < 0.05). On the 8th day, the same patients were given two inhalations with spray 
fluticasone and budesonide (budesonide, 2 inh × 2 mg; Pulmicort 2 inh × 125 mcg). After the inhalations were given, 
Raw and IGTV were measured after 5, 15, 30, 60, and 120 min, SRaw was then calculated.
CONCLUSION: After the preliminary application of doxofylline, the GRs fluticasone and budesonide have a 
significant effect (p < 0.01) on the decrease of the airway SRaw. This effect suggests that the blocking effect of the 
adenosine receptor (p < 0.05) emphasizes the bronchodilation effect of GRs (p < 0.01).
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Introduction
According to recent medical literature, 
significant importance is attributed to caffeine, namely, 
its capability to block adenosine receptors. Adenosine 
receptors act through G-protein, and thus intensively 
studied the possibility of new syntheses and their 
introductions to therapies with specific blockers, which 
are more effective to such receptors. Adenosine causes 
the contraction of the airway’s smooth muscles and 
increases the release of histamine by mastocytes [1].
It is well known that adenosine plays an 
important role in control of the central nervous system 
as well as the cardiovascular, pulmonary, and endocrine 
systems. Adenosine receptors are divided into four 
subtypes: A1, A2, A3, and A4. Receptor A1 is present 
in all the smooth muscles of the vascular system [2] 
mediates the inhibition of creation of adenylate cyclase 
and is responsible for bronchoconstriction. Adenosine 
receptor A1 also promotes sleep by inhibiting the 
cholinergic neuron of the basal part of the frontal brain 
region [3], whereas receptor A2 mediates the stimulation 
of adenylate cyclase and is therefore responsible for 
bronchodilation [4].
Xanthine derivatives, such as caffeine and 
theophylline, act as non-selective antagonists to the 
lung, heart, and brain receptors A1 and A2. As such, 
these derivatives shave an adverse effect on adenosine, 
causing stimulation, or acceleration of the heart rate [5]. 
These compounds act as inhibitors of phosphodiesterase 
(PDE) due to additional anti-inflammatory effects. These 
effects are useful for the treatment of bronchial asthma 
but are less appropriate for research purposes [6].
The presence of adenosine receptor A2A in some 
tissues, such as immune cells, the endothelium and the 
smooth muscles of blood vessels, has been reported 
in the literature. Furthermore, iRNK for receptor A2A, to 
a large extent, is present in the spleen, eye, skeletal 
muscles, lung, heart, and uterus [7], [8], whereas the 
physiological role of the adenosine receptor A2B is found 
in astrocytes, fibroblasts, and blood vessels as well as 
in the gastrointestinal tract [9], [10].
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Adenosine receptor A3 is recognized in terms 
of its specific distribution and expression in different 
types. For example, adenosine receptor A3 is widely 
found in sheep and humans but is less present in mice. 
The pharmacological profile of adenosine receptor A3 in 
humans is like that of sheep [11], [12]. In humans, the 
expression of adenosine receptor A3 is very high in the 
lungs and liver, and lowest in the aorta and brain [13]. In 
the central nervous system, adenosine receptor A3 has 
been studied in neurons and glial cells [14].
In comparison to other adenosine receptors, 
the least is known about receptor A3.
Adenosine receptor third subclass A3 is found 
in the heart and lungs of sheep, and interaction with 
these receptors leads to the inhibition of adenylate 
cyclize [15], [16], [17].
The aim of this paper is to study the effect of 
glucocorticoids (GR) (fluticasone and budesonide) after 
the preliminary application of blockers of adenosine 
receptor (doxofylline, 400 mg tablet) in the treatment of 
patients with bronchial asthma and chronic obstructive 
pulmonary disease (COPD).
Materials and Methods
Fourteen patients with bronchial asthma and 
increased bronchial reactivity were examined for this 
study. For at least 48 h before the study of bronchial 
reactivity response began, the patients were not given 
any bronchodilation substances. The participants 
were informed regarding the method of the functional 
pulmonary tests. Patients in this study had been 
diagnosed with asthma, with or without associated 
COPD. The aim of the examination was explained to 
each patient in advance. Pulmonary function, composed 
of measurement of vital capacity, forced expiratory 
volume in the first s, resistance in the airways (Raw), 
and intrathoracic gas volume (ITGV) were defined at 
rest.
The overall quantity of ITGV was measured with 
the plethysmography method, including non-ventilated 
closed gas. If the residual functional capacity is taken 
from ITGV by plethysmography, information regarding 
the quantity of closed gas due to a severe obstruction, 
cystic lungs, or pneumothorax will be gained. In healthy 
subjects with normal pulmonary function, the volume of 
the intrathoracic gas is equal to the residual functional 
capacity. From the beta and alpha angles, assisted by 
tables, values of the airway resistance and volume of 
the intrathoracic gas were calculated. From gained 
values, specific resistance was calculated:
SRaw = Raw × ITGV
Raw and ITGV were taken for analysis and used 
to calculate the specific resistance (SRaw). Research 
on the bronchial response to different substances was 
performed with the measurements of Raw, ITGV, and 
SRaw as very sensitive indicators of lung function. The 
basic and pulmonary function features of the research 
are provided in Table 1.
Doxofylline, as a blocker of the adenosine 
receptor, was administered for 7 consecutive days 
(2 × 400 mg orally). On the 8th day, Raw, ITGV, and 
SRaw were calculated. Furthermore, on the 8th day, two 
inhalations of spray fluticasone or budesonide were 
applied to the same patients (budesonide, 2 inh. × 2 mg; 
Pulmicort, 2 × 125 mcg inh). Raw and IGTV were 
measured after 5, 15, 30, 60, and 120 min; SRaw was 
then calculated.
Our hypothesis was that changes in the 
respiratory system are not important, not related to the 
development of bronchial asthma or other obstructive 
diseases, and not related to allergic manifestation.
The results were pooled and analyzed. 
Statistical data processing included determination 
of average values (X), standard deviation, standard 
mistake (SEM), and testing of the importance of 
changes in the group of patients treated with adenosine 
receptor blockers. The results were tested with a t-test. 
To compare groups, the statistical test ANOVA was 
used. Potential mistakes with the t-test were avoided 
with the use of ANOVA.
Results
The results of this research in patients with 
COPD and bronchial asthma indicate that doxofylline, 
a blocker of adenosine receptors, caused a significant 
decrease in the airway specific resistance when 
applied on 7 consecutive days at home with a dose of 
2 × 400 mg orally caused a significant decrease in the 
airway specific resistance (p < 0.05) (Figures 1 and 2).
On the 8th day, the same patients were given 
two inhalations with spray fluticasone and budesonide 
(Pulmicort, 2 × 125 mcg inh; budesonide, 2 inh × 
2 mg). Raw and ITGV were then measured after 5, 
15, 30, 60, and 120 min; next, SRaw was calculated. 
After the preliminary application of doxofylline, the GRs 
Table 1: Basic airway characteristics
n Age (years) Height (cm) Weight (kg) VC (L) FEV1 (L) Raw (kPa L/s) ITGV (L) SRaw (kPa L/s)
14 54 ± 1.75 177.1 ± 1.4 75.21 ± 0.7 3.2 ± 2.5 2.85 ± 2.8 0.7 ± 0.3 3.99 ± 1.95 2.79 ± 1.05
Generalized mean values for: VC (L) and FEV1 (L) are also given. VC: Vital capacity expressed in liters, FEV1 – Enhanced expiratory volume in the first second, expressed in liters. Raw (kPa × S/L); ITGV (L); SRaw = Raw 
× ITGV; SGaw = 1/SRaw. Raw – Airway resistance expressed in kilo pascal/second/liter, ITGV – Volume of intrathoracic gas expressed in liters, SRaw: Specific airway resistance which is the relationship between resistance 
and the volume of intrathoracic gas. ITGV: Intrathoracic gas volume.
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fluticasone and budesonide showed a significant effect 
(p < 0.01) on the decrease of airway SRaw. Following 
the administration of the respective substances, there 
were no changes in the heart rate (p > 0.1), (Figure 3).
Initial
values
7 days after
doxofylline
(p<0.05)
5'  after
fluticasone
(p<0.01)
15' 30' 60' 120'
Raw 0.7 0.44 0.38 0.25 0.25 0.24 0.35
ITGV 3.6 3.09 2.96 3.05 2.79 3.17 2.79
SRaw 1.99 1.36 1.12 0.76 0.69 0.76 0.78
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Figure 2: Effects of doxofylline and glucocorticoids: Fluticasone (2 inh 
× 125 mcg) in Raw, intrathoracic gas volume, and specific resistance; 7 
days after administration of doxofylline (2 × 400 mg); (n = 7; X ± SEM)
Discussion
Methylxanthines are efficient in asthma 
treatment, but the mechanism of action is not yet 
clear. Doxofylline is a partially competitive antagonist 
to adenosine receptors. Adenosine may act as an 
autacoid and transmitter of many biologic effects. 
Observations that are of importance to asthma are those 
where adenosine can cause bronchoconstriction in
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Figure 3: Effects of doxofylline and glucocorticoids (fluticasone and 
budesonide) on heart rate; (n = 14; X ± SEM)  
asthmatics and emphasize release of immunologically 
triggered mediators from human mast cells. Therefore, 
blockage of the adenosine effect should be considered 
when efforts are made to explain the effect of 
theophylline [2].
Doxofylline relaxes the smooth muscles 
of the airways effectively, and this bronchodilation 
may contribute to its acute therapeutic efficiency in 
asthma [18].
The antagonisms of both the adenosine 
receptor and the inhibition of PDE can play a role in 
its bronchodilation effect. Adenosine does not contract 
the smooth muscle of human bronchi directly, but after 
being inhaled it acts as a powerful bronchoconstrictor 
to asthmatics. Thus, inhibition of the adenosine function 
can contribute to triggered bronchodilation due to 
theophylline in some of the asthmatics. The activation 
of subtype A2B of the adenosine receptor causes some 
pro-inflammatory effects, and both theophylline and 
enprofylline are powerful competitive antagonists of the 
A2B adenosine receptor [12].
Our previous results indicate that because 
of blockage of the adenosine receptor (doxofylline), 
bronchomotor tonus was reduced significantly 
(p < 0.05) [19]. Blockers of the adenosine receptor 
at applied doses of 400 mg did not cause significant 
change in heart rate and decrease of the systolic and 
diastolic blood pressure (p > 0.1) [20].
The anti-inflammatory effect of doxofylline 
may also appear as a consequence of its capability 
to activate deacetylases in the core. Theoretically, 
deacetylation of histones can reduce the transcription 
of some pro-inflammatory genes and potentiate 
the effect of corticosteroids. Research on the 
development of pharmaceutical preparations is 
geared toward finding safe corticosteroids, i.e., 
corticosteroids, which after oral administration 
has less bioequivalence, less absorbed by lungs, 
and reduced intensity of in activation in systemic 
circulation [21]. All inhaled corticosteroids currently 
in use are absorbed by the lungs and penetrate the 
systemic circulation, while high doses can also cause 
systemic reactions [22], [23], [24].
Short-term research has shown a significant 
slower development in child growth during their 1st year 
of life [25]. Unfinished studies conducted in children 
aged 4–8 years after the completion of a medium 
dosage of inhaled corticosteroids significantly slowed 
the development of female children [26], [27].
Corticosteroids achieve their effect by 
regulating the transcription of some genes. Their 
anti-inflammatory effect is achieved by acting 
on the repressive transcription factors, called 
transpression, while their side effects (endocrine 
and metabolic) are caused by other mechanisms of 
transactivation [28], [29]. The effect of corticosteroids 
(i.e., dissociated corticosteroids) has led to research 
on the separation of the anti-inflammatory mechanism 
from the mechanism responsible for side effects.
Initial values 7 days after
doxofylline
(p<0.05)
5' after
budesonide
(p<0.01)
15' 30' 60' 120'
Raw 0.7 0.37 0.31 0.3 0.32 0.26 0.24
ITGV 3.99 3.78 3.3 3.15 3.19 3.43 3.34
Sraw 2.01 1.53 0.68 0.42 0.43 0.51 0.6
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Figure 1: Effects of doxofylline and glucocorticoids: Budesonide (2 inh 
× 25 mg) in raw, intrathoracic gas volume, and specific resistance; 7 
days after administration of doxofylline (2 × 400 mg); (n = 7; X ± SEM)
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Recent research has shown that the synthesis 
of such dissociated corticosteroids has the best safety 
profile possible. For example, the RU486 antagonist has 
greater transpression capability from transactivation, as 
do some standard steroids (fluticasone propionate and 
budesonide) [30]. Other steroids, such as RU24858 and 
RU40066, also have this capability. At in vivo conditions, 
such corticosteroids have a strong transpression 
effect but only a small transactivation effect [31], 
which indicates the possibility of synthesizing high-
profile oral steroids for the treatment of inflammatory 
diseases. Mice research models show that the anti-
inflammatory effect of GR substance A is a transcription 
factor for corticosteroids. Substance A, as a dissociated 
corticosteroid (does not act in the transactivation), 
does not induce Mitogen-activated protein kinases 
phosphatase 1, unlike dexamethasone. This substance 
activates the GR receptors by causing only the function 
transrepression that inhibits the lymphocyte Th2 
inflammation, thus suppressing the STAT6 translocation 
induced by interleukin-4 cytokines [32], [33]. Other 
molecules with steroid dissociation properties, such 
as ZK245186 and BOL-303242-X, are in the research 
phase [34]. In the current study, therapy with inhaled 
GRs for patients who still had asthma symptoms was 
administered, and agonists of β2-adrenergic receptors 
may be added to the steroid regimen for long duration 
with good results. Once frequently used, today 
methylxanthines are administered less frequently due 
to the modest effects and narrow therapeutic window. 
Selective inhibitors of PDE4, which may have the 
same efficiency but with fewer side effects, are being 
assessed in clinical trials. Other new agents aim to 
affect specific mechanisms, which are important in the 
commencement and progression of asthma. These 
mechanisms include blockers of the adenosine receptor 
and the leukotriene receptor, and therapy with anti-IgE, 
and omalizumab.
Conclusion
Based on our research results, we can 
conclude as follows:
• Doxofylline: Blockers of adenosine receptors 
were applied orally for 7 consecutive days at 
a dose of 2 × 400 mg, caused a significant 
decrease in the SRaw of airways (p < 0.05)
• GRs: After preliminary application of 
doxophylline, budesonide and fluticasone have 
a significant effect (p < 0.01) on the decrease 
of the airways’ SRaw.
This finding suggests that the blocking effect 
of adenosine receptors emphasizes the bronchodilator 
effect of GRs. Thus, finding confirms the idea that 
the activation of deacetylation of histones in the cell 
core (effect of xanthine substances) can decrease 
the transcription of some pro-inflammatory genes and 
potentiate the effect of corticosteroids.
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